Mary Lynne Hedley, Ph.D.
Senior Scientific Fellow, Broad Institute of MIT and Harvard
Hedley is a Senior Scientific Fellow at the Broad Institute of MIT and Harvard. Prior to that, she served as Director, President and Chief Operating Officer at TESARO, Inc., a biotechnology company she co-founded in 2010, focused on the development and global commercialization of oncology therapeutics. TESARO was acquired by GlaxoSmithKline plc in 2019. She was elected to the Eli Lilly and Company board of directors in 2022.
Prior to founding TESARO, Hedley was executive vice president and chief science officer of Abraxis Bioscience, Inc., responsible for research and development, operations, medical affairs and business development. From January 2008 until July 2009, she was executive vice president of Eisai Corporation of North America, with a focus on the global reorganization of its research and development program and building a global oncology strategy. Hedley served in various positions at MGI Pharma, Inc. from 2004 through its acquisition in January 2008, most recently as executive vice president and chief scientific officer. Prior to that, Hedley co-founded and served as the president and chief executive officer of Zycos, Inc., a biotechnology company acquired by MGI Pharma, Inc. in 2004.
Hedley received her bachelor’s degree in microbiology from Purdue University and a doctorate in molecular and cellular immunology from UT Southwestern Medical Center. Hedley completed her postdoctoral training at Harvard University in immunology and gene regulation.
Hedley sits on the boards of Helsinn Healthcare SA, Veeva Systems, Inc., Centessa Pharmaceuticals plc, Youville Assisted Living Communities, and WITH (Women Innovating Together in Healthcare).
